Shares of Insmed skyrocketed after the company posted positive Phase II results for INS1007 as a potential treatment for adults with non-cystic fibrosis bronchiectasis (NCFBE).

Pneumonia killed more than 800,000 babies and young children during 2018 – or one child every 39 seconds – despite being curable and mostly preventable, global health agencies said.

Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.

The U.S. Food and Drug Administration gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease.

Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.

Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.

Theravance Biopharma Inc. and partner Mylan NV won U.S. regulatory approval for their treatment Yupelri for a chronic lung condition that causes breathing-related problems.

J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.

The Food and Drug Administration approved Insmed Inc.’s lead drug Arikayce to treat a rare chronic lung disease.

A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.